Overview

Phase III Study of Florbetaben (BAY94-9172) PET Imaging for Detection/Exclusion of Cerebral β-amyloid Compared to Histopathology

Status:
Completed
Trial end date:
2013-12-01
Target enrollment:
Participant gender:
Summary
To determine the sensitivity and specificity of the visual assessment of tracer uptake in the Florbetaben PET images compared to histological verification of the presence or absence of cerebral β-amyloid in the respective histopathologic post mortem specimens as the standard of truth
Phase:
Phase 3
Details
Lead Sponsor:
Life Molecular Imaging SA
Piramal Imaging SA